Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations
Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations
Recruiting · NCT07252479 · Registry updated 2026-06-08Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations | RAS Mutation; Solid Tumors (Phase 1) | Recruiting | Phase 1 | 2026-06-08 | NCT07252479 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Adlai Nortye Biopharma Co., Ltd. | 4 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| H. Lee Moffit Cancer Center and Research Institute Hospital, Inc. | Tampa | United States | 1 |
| Sarah Cannon Research Institute at Florida Cancer Specialists | Orlando | United States | 11 |
| University of Texas MD Anderson Cancer Center | Houston | United States | 192 |